Literature DB >> 33902632

Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.

Henriette Schermacher Marstein1,2, Kristin Godang3, Berit Flatø4,5, Ivar Sjaastad6,7, Jens Bollerslev3,4, Helga Sanner8,5.   

Abstract

BACKGROUND: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children and adolescents. Both the disease and its treatment with glucocorticoids may negatively impact bone formation. In this study we compare BMD in patients (children/adolescence and adults) with long-standing JDM with matched controls; and in patients, explore how general/disease characteristics and bone turnover markers are associated with BMD.
METHODS: JDM patients (n = 59) were examined median 16.8y (range 6.6-27.0y) after disease onset and compared with 59 age/sex-matched controls. Dual-energy X-ray absorptiometry (DXA) was used to measure BMD of the whole body and lumbar spine (spine) in all participants, and of ultra-distal radius, forearm and total hip in participants ≥20y only. Markers of bone turnover were analysed, and associations with outcomes explored.
RESULTS: Reduced BMD Z-scores (<-1SD) were found in 19 and 29% of patients and 7 and 9% of controls in whole body and spine, respectively (p-values < 0.05). BMD and BMD Z-scores for whole body and spine were lower in all patients and for < 20y compared with their respective controls. In participants ≥20y, only BMD and BMD Z-score of forearm were lower in the patients versus controls. In patients, BMD Z-scores for whole body and/or spine were found to correlate negatively with prednisolone use at follow-up (yes/no) (age < 20y), inflammatory markers (age ≥ 20y) and levels of interferon gamma-induced protein 10 (IP-10) (both age groups). In all patients, prednisolone use at follow-up (yes/no) and age ≥ 20y were independent correlates of lower BMD Z-scores for whole body and spine, respectively.
CONCLUSION: In long-term JDM, children have more impairment of BMD than adults in spine and whole-body. Associations with BMD were found for both prednisolone and inflammatory markers, and a novel association was discovered with the biomarker of JDM activity, IP-10.

Entities:  

Keywords:  Bone mineral density; DXA; IP-10; Inflammatory markers; Juvenile dermatomyositis; Prednisolone

Year:  2021        PMID: 33902632     DOI: 10.1186/s12969-021-00543-z

Source DB:  PubMed          Journal:  Pediatr Rheumatol Online J        ISSN: 1546-0096            Impact factor:   3.054


  35 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

Review 2.  Bone loss in inflammatory disorders.

Authors:  R Hardy; M S Cooper
Journal:  J Endocrinol       Date:  2009-06       Impact factor: 4.286

Review 3.  Role of phosphate sensing in bone and mineral metabolism.

Authors:  Sampada Chande; Clemens Bergwitz
Journal:  Nat Rev Endocrinol       Date:  2018-11       Impact factor: 43.330

4.  Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Authors:  L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2014-08-22       Impact factor: 4.507

5.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

Review 6.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  J Nishimura; S Ikuyama
Journal:  J Bone Miner Metab       Date:  2000       Impact factor: 2.626

7.  Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise.

Authors:  Khayriah A Alsufyani; Olivia Ortiz-Alvarez; David A Cabral; Lori B Tucker; Ross E Petty; Helen Nadel; Peter N Malleson
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

8.  Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.

Authors:  Mai Kawazoe; Kaichi Kaneko; Kotaro Shikano; Natsuko Kusunoki; Toshihiro Nanki; Shinichi Kawai
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

9.  International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.

Authors:  Samuel Vasikaran; Cyrus Cooper; Richard Eastell; Andrea Griesmacher; Howard A Morris; Tommaso Trenti; John A Kanis
Journal:  Clin Chem Lab Med       Date:  2011-05-24       Impact factor: 3.694

10.  Association Between Age at Puberty and Bone Accrual From 10 to 25 Years of Age.

Authors:  Ahmed Elhakeem; Monika Frysz; Kate Tilling; Jon H Tobias; Deborah A Lawlor
Journal:  JAMA Netw Open       Date:  2019-08-02
View more
  1 in total

1.  Evaluation of an Ionic Calcium Fiber Supplement and Its Impact on Bone Health Preservation in a Dietary Calcium Deficiency Mice Model.

Authors:  Sara Elisa Herrera-Rodríguez; Eristeo García-Márquez; Eduardo Padilla-Camberos; Hugo Espinosa-Andrews
Journal:  Nutrients       Date:  2022-01-18       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.